Showing results (21-30 of 32) with videos related to
Sort By:
Pageof 4
Neurology(R) Neuroimmunology & Neuroinflammation|January 20, 2022
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control StudyPietro Iaffaldano, Giuseppe Lucisano, Alessia Manni, et al.Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 7, 2024
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara G Chisari, Umberto Aguglia, Maria Pia Amato, et al.Journal of Neurology|May 28, 2024
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progressionEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.Brain : a Journal of Neurology|September 16, 2020
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosisMaria Pia Amato, Mattia Fonderico, Emilio Portaccio, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 16, 2022
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS RegisterPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.Multiple Sclerosis and Related Disorders|October 26, 2022
The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control studyMarta Ponzano, Irene Schiavetti, Roberto Bergamaschi, et al.Journal of Neurology|June 28, 2021
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara G Chisari, Giancarlo Comi, Massimo Filippi, et al.Neurology(R) Neuroimmunology & Neuroinflammation|January 28, 2026
Validation of the MOG-AR Score: A Retrospective Multicenter StudySara Carta, Riccardo Tiberi, Nicola De Rossi, et al.JAMA Neurology|November 27, 2023
Multiple Sclerosis Progression and Relapse Activity in ChildrenPietro Iaffaldano, Emilio Portaccio, Giuseppe Lucisano, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 4, 2026
Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study)Damiano Paolicelli, Giuseppe Lucisano, Alessia Manni, et al.Pageof 4